Cell Transfection Market Report 2024

This Cell Transfection market report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The cell transfection market size has grown strongly in recent years. It will grow from $1.19 billion in 2023 to $1.29 billion in 2024 at a compound annual growth rate (CAGR) of 9%. The growth during the historic period can be attributed to a surge in CRISPR and gene editing research, increased funding from governments and non-governmental organizations, a rise in clinical trials involving transfected cells, the expansion of academic research in molecular biology, and the growing popularity of high-throughput screening methods.

The cell transfection market size is expected to see strong growth in the next few years. It will grow to $1.83 billion in 2028 at a compound annual growth rate (CAGR) of 9.1%. The growth during the forecast period can be attributed to the increasing demand for gene therapy, the rising prevalence of chronic diseases, the expansion of biopharmaceutical manufacturing, growth in proteomics and genomics research, and the expanding applications of RNA-based therapeutics. Major trends expected include rising investment in biotech and pharmaceutical research and development, advancements in transfection technologies, the adoption of personalized medicine, the use of transfection in cancer research, and the development of novel transfection reagents and kits.

The rising incidence of infectious diseases is expected to drive the growth of the cell transfection market. Infectious diseases, caused by germs that spread through person-to-person contact or contaminated sources, have become more prevalent due to inadequate public health infrastructure, vaccine hesitancy, and misinformation. Cell transfection is a valuable tool for studying these diseases, as it allows researchers to introduce genes into cells to understand how infections affect them and to test new treatments. For example, a report from the Australian Bureau of Statistics in September 2023 noted that the death rate from influenza and pneumonia increased from 31.5 per 100,000 in 2021 to 42.6 per 100,000 in 2022. This rise in infectious disease cases is fueling the demand for cell transfection technologies.

Leading companies in the cell transfection market are incorporating innovations into their transfection systems to allow for precise control over gene expression. A transfection system introduces foreign nucleic acids into cells to study gene function, produce proteins, or modify gene expression. For instance, in July 2024, STEMCELL Technologies, a Canadian biotechnology firm, introduced the Cellpore transfection system. This advanced tool uses microfluidic technology to improve the delivery of macromolecules into cells, overcoming limitations of traditional methods. The system can handle up to 10 million cells per second and is suitable for large-scale applications. It works with various cell types, including T cells and hematopoietic stem cells, and can deliver different types of cargo, such as small molecules, RNA, proteins, and antibodies.

In July 2023, Sartorius AG, a German provider of pharmaceutical and laboratory equipment, acquired Polyplus-Transfection SA for $2.6 billion (€2.4 billion). This acquisition positions Sartorius and Polyplus as major players in the cell and gene therapies market, combining Sartorius's expertise with Polyplus's leadership in innovative cell transfection solutions. Polyplus-Transfection SA is a French company specializing in cell transfection technologies.

Major companies operating in the cell transfection market are Thermo Fisher Scientific Inc., Merck KGaA, Agilent Technologies Inc., Lonza Group AG, Sartorius AG, Sigma-Aldrich Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., Stemcell Technologies Inc., GenScript Biotech Corporation, Promega Corporation, Takara Bio Inc., Molecular Devices LLC, New England Biolabs Inc., CureVac SE, OriGene Technologies Inc., Tocris Bioscience, Vector Biolabs, Mirus Bio LLC, Addgene Inc., Altogen Biosystems, Cell Biolabs Inc., Cellecta Inc., ExCell Bio Inc., GeneCopoeia Inc.

North America was the largest region in the cell transfection market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cell transfection market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the cell transfection market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Cell transfection is a technique in molecular biology used to introduce nucleic acids such as DNA, RNA, or oligonucleotides into eukaryotic cells. This method enables researchers to investigate gene function, protein expression, and other cellular processes by altering the genetic material of the cells. It is an essential tool in genetic engineering, drug discovery, and various areas of biomedical research.

The main methods of cell transfection include electroporation, lipofection, calcium phosphate, viral transfection, and others. Electroporation involves applying brief electrical pulses to create temporary pores in cell membranes, allowing genetic material or molecules to enter the cell. This technique is used for biomedical research, therapeutic delivery, and protein production by various end users, including academic and research institutes, pharmaceutical and biotechnology companies, contract research organizations, and others.

The cell transfection market research report is one of a series of new reports that provides cell transfection market statistics, including cell transfection industry global market size, regional shares, competitors with a cell transfection market share, detailed cell transfection market segments, market trends and opportunities, and any further data you may need to thrive in the cell transfection industry. This cell transfection market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cell transfection market consists of revenues earned by entities by providing services such as stable cell line development, high-throughput transfection, transient transfection services and viral vector production. The market value includes the value of related goods sold by the service provider or included within the service offering. The cell transfection market also includes sales of reagents, kits, electroporation systems and other related products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.